Richter did not disclose the financial terms of the agreement. “This transaction is considered to be a further strategic move to strengthen Richter’s direct position in Latin America and at the same time to become gradually a global female healthcare player”, said CEO Erik Bogsch.

Richter obtained from HRA Pharma an extension of its geographical scope for Esmya to the CIS and China in December 2011. A year ago, Richter entered into a licencing agreement with HRA Pharama in connection with market rights in Latin America for ulipristal acetate.

Watson Pharmaceuticals has exclusive rights to develop and market Esmya in the United States and Canada.